---
title: "CAPR 截止日期：ROSEN，作為值得信賴的投資者顧問，建議 Capricor 治療公司投資者在證券集體訴訟的重要截止日期前尋求法律顧問"
description: "紐約，2025 年 8 月 30 日（GLOBE NEWSWIRE）——為什麼：羅森律師事務所，一家全球投資者權益律師事務所，提醒在 2024 年 10 月 9 日至 2025 年 7 月 10 日期間（包括這兩個日期）購買 Capricor Therapeutics, Inc.（股票代碼：CAPR）證券的投資者注意重要的 9 月 15 日"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/255313980.md"
published_at: "2025-08-30T13:36:39.000Z"
---

# CAPR 截止日期：ROSEN，作為值得信賴的投資者顧問，建議 Capricor 治療公司投資者在證券集體訴訟的重要截止日期前尋求法律顧問

> 紐約，2025 年 8 月 30 日（GLOBE NEWSWIRE）——為什麼：羅森律師事務所，一家全球投資者權益律師事務所，提醒在 2024 年 10 月 9 日至 2025 年 7 月 10 日期間（包括這兩個日期）購買 Capricor Therapeutics, Inc.（股票代碼：CAPR）證券的投資者注意重要的 9 月 15 日

NEW YORK, Aug. 30, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. CAPR between October 9, 2024 and July 10, 2025, both dates inclusive ( the "Class Period" ) , of the important September 15, ...

### Related Stocks

- [CAPR.US - Capricor治療](https://longbridge.com/zh-HK/quote/CAPR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4% | Capricor Therapeutics, Inc. (NASDAQ:CAPR) saw a 69.4% decrease in short interest in December, with shares sold short tot | [Link](https://longbridge.com/zh-HK/news/270785955.md) |
| Capricor Therapeutics Unveils Investor Presentation Highlighting Duchenne Program and Exosome Platform | Capricor Therapeutics Inc. has released an investor presentation detailing updates on its Duchenne muscular dystrophy tr | [Link](https://longbridge.com/zh-HK/news/274992906.md) |
| How Investors May Respond To Capricor Therapeutics (CAPR) Phase 3 HOPE-3 Success And $150 Million Equity Raise | Capricor Therapeutics completed a $150 million public offering after positive Phase 3 HOPE-3 results for Deramiocel in D | [Link](https://longbridge.com/zh-HK/news/269428805.md) |
| Roth MKM Keeps Their Buy Rating on Capricor Therapeutics (CAPR) | Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Capricor Therapeutics with a $41 price target. The ana | [Link](https://longbridge.com/zh-HK/news/268620819.md) |
| Capricor Therapeutics Reports Positive Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy | Capricor Therapeutics announced positive Phase 3 results for Deramiocel in treating Duchenne muscular dystrophy. The HOP | [Link](https://longbridge.com/zh-HK/news/268427206.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
